ES2104635T3 - Nuevo peptido porcino con una actividad fisiologica (cnp-53). - Google Patents

Nuevo peptido porcino con una actividad fisiologica (cnp-53).

Info

Publication number
ES2104635T3
ES2104635T3 ES91111629T ES91111629T ES2104635T3 ES 2104635 T3 ES2104635 T3 ES 2104635T3 ES 91111629 T ES91111629 T ES 91111629T ES 91111629 T ES91111629 T ES 91111629T ES 2104635 T3 ES2104635 T3 ES 2104635T3
Authority
ES
Spain
Prior art keywords
cnp
physiological activity
new porcine
porcine peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91111629T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2104635T3 publication Critical patent/ES2104635T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBE UN PEPTIDO COMPUESTO DE 53 RESIDUOS DE AMINO ACIDO REPRESENTADO POR LA SIGUIENTE SECUENCIA DE AMINO ACIDO: Y SUS DERIVADOS REPRESENTADOS POR LA SIGUIENTE SECUENCIA DE AMINO ACIDO: DONDE X ES COMO SE MUESTRA EN LA ESPECIFICACION. ESTOS POLIPEPTIDOS SON NUEVOS Y TIENEN ACCIONES NATRIURETICAS E HIPOTENSORAS.
ES91111629T 1990-07-13 1991-07-12 Nuevo peptido porcino con una actividad fisiologica (cnp-53). Expired - Lifetime ES2104635T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2186582A JP2930380B2 (ja) 1990-07-13 1990-07-13 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）

Publications (1)

Publication Number Publication Date
ES2104635T3 true ES2104635T3 (es) 1997-10-16

Family

ID=16191066

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91111629T Expired - Lifetime ES2104635T3 (es) 1990-07-13 1991-07-12 Nuevo peptido porcino con una actividad fisiologica (cnp-53).

Country Status (8)

Country Link
US (1) US5340920A (es)
EP (1) EP0466174B1 (es)
JP (1) JP2930380B2 (es)
AT (1) ATE154641T1 (es)
DE (1) DE69126568T2 (es)
DK (1) DK0466174T3 (es)
ES (1) ES2104635T3 (es)
GR (1) GR3024581T3 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1118329A4 (en) * 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
KR20070007842A (ko) 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
EP2432489B1 (en) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DE69126568T2 (de) 1997-11-27
JPH0474198A (ja) 1992-03-09
DK0466174T3 (da) 1998-01-12
GR3024581T3 (en) 1997-12-31
EP0466174B1 (en) 1997-06-18
JP2930380B2 (ja) 1999-08-03
ATE154641T1 (de) 1997-07-15
DE69126568D1 (de) 1997-07-24
US5340920A (en) 1994-08-23
EP0466174A1 (en) 1992-01-15

Similar Documents

Publication Publication Date Title
GR3024581T3 (en) Novel physiologically active porcine peptide (CNP-53)
DK81685D0 (da) Biologisk aktivt peptid og terapeutisk middel indeholdende et saadantpeptid
DK0475394T3 (da) Rotte C-type natriuretisk peptid cDNA, og precursorprotein
DK0466175T3 (da) Porcint CNP-gen og præcursor-protein
SE8605189L (sv) Nya kalcitoninderivat
DK193887A (da) Peptid med bronchodilartorisk og hypotensiv aktivitet
ATE140962T1 (de) Dns-klone von menschlichem thrombomodulin
SE7712634L (sv) Ny polypeptid med serumkalciumreducerande aktivitet
SE8702520D0 (sv) Mammal intestine hormone precursor
ATE216706T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
AU2254588A (en) Biologically active segments of several growth hormones
DK0475842T3 (da) Ekspressionskassette for et forstadium af endothiapepsin i Cryphonectria parasitica
ES2066964T3 (es) Una proteina reg.
ATE75486T1 (de) Anorexigenische und hypotensive peptide.
SE9603461D0 (sv) New compounds
ITFI920071A1 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk
ATE416781T1 (de) Antigene modifikation von polypeptiden
DK198990D0 (da) Biologisk aktivt polypeptid og fremgangsmaade til omdannelse af dette til et modent protein
DK53290A (da) Syntetiske gaer-leader-peptider
EP0266006A3 (en) Novel hypotensive diuretic peptides

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 466174

Country of ref document: ES